Stockreport

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics, Inc.  (IKT) 
PDF WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company d [Read more]